Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

By A. Camm, Paulus Kirchhof, G. Lip, Ulrich Schotten, I. Savelieva, S. Ernst, I. V. van Gelder, N. Al-Attar, Gerhard Hindricks, B. Prendergast and 57 more. Europace, 2010

4,092 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Economics and Econometrics

View Paper: https://www.semanticscholar.org/paper/6e0f1b7bcb06402741a8ec4fa76170b6d80bf5f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. (2013, background): “Classification of AF sub-types reflects this natural history comprising “first diagnosed” AF, self-terminating paroxysmal episodes (transient to persistent) and the long-standing and permanent form of AF that defies attempts to achieve sinus rhythm [1].”
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. (2012, background): “New-onset AF (or flutter) is diagnosed as any arrhythmia within hospitalization that has the ECG characteristics of AF and lasts sufficiently long to be recorded on a 12-lead ECG, or for at least 30 s on a rhythm strip [35].”
AF Classification from a Short Single Lead ECG Recording: the PhysioNet/Computing in Cardiology Challenge 2017 (2017, neutral): “[2].”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, neutral): “Recommendations for antithrombotic therapy should be based on the presence (or absence) of risk factors for stroke and thrombo-embolism, and we refer further to the recent guidelines of the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology.(516,517)”
ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “Current therapy is based onvitamin Kantagonistsbut newerdrugs, either direct thrombin inhibitors (dabigatran) or factor Xa inhibitors (rivaroxaban, apixaban) have been shown to be non-inferior and sometimes superior to warfarin.(561,563) They are promising newcomers in this therapeutic field, althou”
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, neutral): “markedly reduced LVEF, but this has not been shown to reduce mortality or sudden death in these patients.(8,340) In the RAFT trial, 229 (or 13% of the total population of 1798) patients had AF or flutter at baseline.”